Combination of Luteolin and Solifenacin Improves Urinary Dysfunction Induced by Diabetic Cystopathy in Rats

Background The purpose of the present study was to assess the effect of luteolin and solifenacin on diabetic cystopathy (DCP) and to investigate the mechanism of action. A novel link between the overexpression of c-Kit in the bladder and voiding dysfunction was identified in rats with DCP. Material/Methods A rat model of DCP was successfully established by intraperitoneal injection of streptozotocin and a diet high in glucose and lipids, and animals were treated with luteolin and solifenacin. The effect of luteolin and solifenacin on urinary dysfunction in DCP rats was investigated by assessing bladder pressure and performing a volume test. The protein levels of c-Kit, stem cell factor (SCF), p110, and phosphorylated p110 in the bladder were detected by Western blot analysis and immunohistochemical staining. Results In DCP rats, the protein levels of c-Kit, SCF and phosphorylated p110 in the bladder were significantly increased. However, oral treatment of DCP rats with luteolin combined with solifenacin resulted in effective improvement of overactive bladder and reduced the protein expression of c-Kit, SCF, and phosphorylated p110. Moreover, the effect of luteolin combined with solifenacin on maximum voiding pressure and residual urine volume was improved compared to that of luteolin alone. Conclusions Luteolin improved overactive bladder in DCP rats, which may be due to SCF/c-kit inhibition, as well as the downregulation of the phosphoinositide-3 kinase signaling pathway. Moreover, solifenacin enhanced the potential pharmacological effect of luteolin in the treatment of DCP.

[1]  M. Ellersieck,et al.  Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. , 2016, Oncology reports.

[2]  H. Yılmaz,et al.  Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder , 2016, International Urogynecology Journal.

[3]  M. Moridani,et al.  Bioactivation of luteolin by tyrosinase selectively inhibits glutathione S-transferase. , 2015, Chemico-biological interactions.

[4]  P. Geavlete,et al.  Combination therapy using solifenacin and mirabegron for OAB patients , 2015 .

[5]  Hongyu Kuang,et al.  Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[6]  Cheng Guo,et al.  Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[7]  S. Sadjadi,et al.  Uremic Pericarditis: A Report of 30 Cases and Review of the Literature , 2015, The American journal of case reports.

[8]  Xiang Mu,et al.  Luteolin prevents fMLP-induced neutrophils adhesion via suppression of LFA-1 and phosphodiesterase 4 activity , 2015 .

[9]  T. Drewa,et al.  Cajal–like interstitial cells as a novel target in detrusor overactivity treatment: true or myth? , 2013, Central European journal of urology.

[10]  D. Yoon,et al.  Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. , 2014, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[11]  Ding Zhao,et al.  Berberine improves neurogenic contractile response of bladder detrusor muscle in streptozotocin-induced diabetic rats. , 2013, Journal of ethnopharmacology.

[12]  S. Jung,et al.  Raf and PI3K are the Molecular Targets for the Anti‐metastatic Effect of Luteolin , 2013, Phytotherapy research : PTR.

[13]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[14]  H. Akino,et al.  Co‐administration of an α1‐blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity , 2011, International journal of urology : official journal of the Japanese Urological Association.

[15]  Xinmin Liu,et al.  Luteolin protects against reactive oxygen species‐mediated cell death induced by zinc toxicity via the PI3K–Akt–NF‐κB–ERK‐dependent pathway , 2011, Journal of neuroscience research.

[16]  F. Fang,et al.  Luteolin improves contractile function and attenuates apoptosis following ischemia-reperfusion in adult rat cardiomyocytes. , 2011, European journal of pharmacology.

[17]  Min Zhang,et al.  Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1α under normoxic condition. , 2011, Cancer letters.

[18]  R. Lang,et al.  Functions of ICC-like cells in the urinary tract and male genital organs , 2010, Journal of cellular and molecular medicine.

[19]  A. Fayyad,et al.  Prevalence and risk factors for bothersome lower urinary tract symptoms in women with diabetes mellitus from hospital-based diabetes clinic , 2009, International Urogynecology Journal.

[20]  L. Baolin,et al.  Evaluation of the Anti-inflammatory Activity of Luteolin in Experimental Animal Models , 2007, Planta medica.

[21]  M. Saito,et al.  Ability of cyclohexenonic long-chain fatty alcohol to reverse diabetes-induced cystopathy in the rat. , 2007, European urology.

[22]  S. Biers,et al.  The functional effects of a c‐kit tyrosine inhibitor on guinea‐pig and human detrusor , 2006, BJU international.

[23]  S. K. Van Den Eeden,et al.  Urologic complications in diabetes. , 2022, Journal of diabetes and its complications.

[24]  R. Roskoski.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[25]  M. Weiss,et al.  Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation , 2005, Molecular and Cellular Biology.

[26]  R. Lang,et al.  Interstitial cell of Cajal‐like cells in the upper urinary tract , 2005, Journal of cellular and molecular medicine.

[27]  U. Rolle,et al.  Interstitial cells of Cajal in the human normal urinary bladder and in the bladder of patients with megacystis‐microcolon intestinal hypoperistalsis syndrome , 2004, BJU international.

[28]  A. C. Buck,et al.  Bladder dysfunction and neuropathy in diabetes , 1976, Diabetologia.

[29]  P. Puri,et al.  Altered expression of interstitial cells of Cajal in congenital ureteropelvic junction obstruction. , 2003, The Journal of urology.

[30]  H. Ueda,et al.  Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. , 2002, Biological & pharmaceutical bulletin.

[31]  D. Metcalfe,et al.  Kit signal transduction. , 2000, Hematology/oncology clinics of North America.

[32]  J. Orth,et al.  Gonocytes in testes of neonatal rats express the c‐kit gene , 1996, Molecular reproduction and development.

[33]  L. S. Mitteness.  Knowledge and Beliefs about Urinary Incontinence in Adulthood and Old Age , 1990, Journal of the American Geriatrics Society.

[34]  B. Uvelius,et al.  Bladder function in rats with short- and long-term diabetes; effects of age and muscarinic blockade. , 1989, The Journal of urology.

[35]  Moller Cf.  Diabetic cystopathy. III:Urinary bladder dysfunction in relation to bacteriuria. , 1976 .

[36]  Moller Cf,et al.  Diabetic cystopathy. IV: Micturition cystourethrography compared with urodynamic investigation. , 1976 .

[37]  C. F. Moller.  Diabetic cystopathy. III:Urinary bladder dysfunction in relation to bacteriuria. , 1976, Danish medical bulletin.

[38]  K. Olesen,et al.  Diabetic cystopathy. IV: Micturition cystourethrography compared with urodynamic investigation. , 1976, Danish medical bulletin.

[39]  A. C. Buck,et al.  The Diabetic Bladder , 1974, Proceedings of the Royal Society of Medicine.

[40]  W. R. Jordan,et al.  PARALYSIS OF THE BLADDER IN DIABETIC PATIENTS , 1935 .